Insulin lispro - Biologic Drug Details

Summary for insulin lispro

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	6
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for insulin lispro
Drug Prices:	Drug price information for insulin lispro

Recent Clinical Trials for insulin lispro

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Rutgers, The State University of New Jersey	NA
Centre for Addiction and Mental Health	PHASE4
The Physicians' Services Incorporated Foundation	PHASE4

See all insulin lispro clinical trials

Pharmacology for insulin lispro

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin lispro Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin lispro Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	205747	5,474,978	2014-06-16	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	205747	5,514,646	2013-05-07	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADMELOG	insulin lispro	Injection	209196	10,213,556	2036-05-24	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADMELOG	insulin lispro	Injection	209196	5,474,978	2014-06-16	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADMELOG	insulin lispro	Injection	209196	5,958,881	2017-10-24	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADMELOG	insulin lispro	Injection	209196	7,163,923	2022-05-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin lispro Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	10,004,686	2033-06-12	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	10,016,338	2036-12-20	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	10,124,040	2035-08-21	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	10,155,799	2035-07-16	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	10,172,922	2036-09-08	Patent claims search
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	10,182,561	2036-06-14	Patent claims search

International Patents for insulin lispro

Country	Patent Number	Estimated Expiration
Spain	2659862
El Salvador	2004001556
Japan	2015071632
Costa Rica	7614
South Africa	200810475
Portugal	2305288

Market Dynamics and Financial Trajectory for Insulin Lispro

Last updated: February 19, 2026

What Is the Current Market Size for Insulin Lispro?

Insulin lispro is a rapid-acting insulin analog used in diabetes management. The global insulin market was valued at approximately $27 billion in 2022, with rapid-acting insulins accounting for around 40% of that segment, roughly $10.8 billion. Insulin lispro's market share within rapid-acting insulins is estimated at 60%. Therefore, the global market for insulin lispro was approximately $6.5 billion in 2022.

How Has the Market for Insulin Lispro Evolved Recently?

The insulin market has experienced consistent growth driven by increasing diabetes prevalence:

• Global Diabetes Prevalence: 537 million adults in 2021, projected to reach 643 million by 2030 (IDF, 2021).
• Insulin Pen Market Penetration: Over 70% of insulin users now administer via pens, increasing demand for rapid-acting formulations.
• Market Growth Rate: Estimated annual compound growth rate (CAGR) of 5.5% for insulin products from 2022 to 2030.

Entry of biosimilar insulin lispro formulations has intensified competition, influencing pricing and market dynamics.

Who Are the Key Market Players for Insulin Lispro?

Major manufacturers include:

• Eli Lilly: Originator of Humalog (insulin lispro).
• Sanofi: Produces Admelog (biosimilar insulin lispro).
• Biocon: Markets its biosimilar formulations.
• Novo Nordisk and Others: Focus on developing innovative insulin delivery systems and formulations.

Eli Lilly maintains approximately a 55% market share in insulin lispro sales, with biosimilar competitors capturing the remaining market share.

How Do Regulatory Approvals Affect Market Access?

Regulatory pathways significantly influence market geography and product availability:

• FDA Approvals (U.S.): Humalog approved since 1996; biosimilars like Admelog approved in 2017.
• EMA Approvals (Europe): Biosimilars approved since 2016, increasing accessibility.
• Emerging Markets: Regulatory approval delays and price controls affect sales volume.

Market entry of biosimilars typically reduces prices by 20-30%, impacting profit margins for originators.

What Are the Drivers and Barriers for Growth?

Drivers:

• Increasing diabetes prevalence.
• Advancements in insulin delivery devices.
• Rising adoption of biosimilars reducing costs.
• Growing demand in emerging markets.

Barriers:

• Patent expirations leading to generic biosimilar entries.
• Price sensitivity among healthcare systems.
• Regulatory hurdles.
• Competition from novel insulin formulations, such as ultra-rapid or concentrated insulins.

What Are Future Revenue Projections?

Forecasts suggest the insulin lispro market will reach approximately $9 billion by 2030, growing at a CAGR of 4.8% from 2022. Factors fueling this growth include:

• Widening access due to biosimilars.
• Innovation in delivery systems.
• Expansion in developing countries.

Eli Lilly and Sanofi are expected to maintain dominant positions, with biosimilar entrants capturing an increasing share.

How Do Biosimilar Insulin Lispro Affect Financial Trajectories?

Biosimilar insulin lispro formulations entered multiple markets from 2016 onward. They typically underprice brand-name products by 20% to 30%. This leads to:

• Marginal revenue reductions for originators.
• Increased volume sales volumes driven by lower prices.
• Contractual licensing and partnership deals to manage market penetration.

Eli Lilly reported a 10% decline in Humalog revenue in 2021, attributed partly to biosimilar competition.

What Is the Impact of Delivery Technologies on Market Growth?

Devices such as insulin pens and connected insulin pens enhance adherence, facilitating incremental revenue. Investment in digital health solutions and smart delivery devices enables:

• Real-time data tracking.
• Remote management.
• Premium pricing for integrated solutions.

Insulin lispro formulations integrated with these devices are projected to see double-digit growth rates.

How Do Policy and Reimbursement Landscape Shapes Market Trajectory?

Reimbursement policies:

• Favor biosimilar uptake where cost containment is prioritized.
• Dictate distribution channels.
• Influence manufacturer pricing strategies.

In the U.S., Medicare Part D covers insulin, including biosimilars, with formulary preferences affecting sales.

Summary of Key Trends

Trend	Impact
Patent expirations	Increased biosimilar competition
Innovation in delivery	Higher adherence, premium pricing
Emerging markets growth	Expanded user base
Regulatory approvals	Market access expansion
Digital health integration	Value-added services

Key Takeaways

• The insulin lispro market was valued at $6.5 billion in 2022, with expected growth to near $9 billion by 2030.
• Biosimilars are the primary competitive threat, leading to price reductions and market share rerouting.
• Eli Lilly remains the market leader, but biosimilar entrants and new delivery technologies are reshaping the competitive landscape.
• Regulatory policies and reimbursement systems determine pace and extent of market penetration.
• Innovation in delivery devices and digital health support growth by enhancing treatment adherence and premium offerings.

FAQs

What is insulin lispro used for?

Insulin lispro is used for blood sugar control in people with type 1 and type 2 diabetes. It acts rapidly to manage post-meal glucose spikes.

How does biosimilar insulin lispro impact market prices?

Biosimilars typically reduce prices by 20–30%. Their entry increases affordability but pressures originator revenues.

What are the main barriers for biosimilar insulin lispro adoption?

Barriers include regulatory delays, brand loyalty, patent litigations, and healthcare provider inertia.

How is innovation influencing the insulin market?

Advancements in delivery devices and digital health improve adherence and enable premium pricing strategies.

What is the outlook for emerging markets?

Increasing diabetes prevalence and healthcare infrastructure investment create substantial growth opportunities, particularly where biosimilar adoption is encouraged.

---

Sources

1. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th Edition.
2. IQVIA. (2022). Global Insulin Market Reports.
3. FDA. (2017). Approval of Admelog (insulin lispro inj.).
4. EMA. (2016). Approval of biosimilar insulin lispro.
5. Eli Lilly. (2022). Annual Financial Report.